George A. Eldridge - Dec 9, 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Officer Title: Chief Financial Officer and Treasurer
Signature
/s/ George A. Eldridge
Stock symbol
AVTE
Transactions as of
Dec 9, 2022
Transactions value $
-$367,300
Form type
4
Date filed
12/13/2022, 05:00 PM
Previous filing
Dec 9, 2022
Next filing
Feb 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $8.49K +3.97K +202.5% $2.14* 5.93K Dec 9, 2022 Direct F1
transaction AVTE Common Stock Sale -$82.1K -3.39K -57.11% $24.23 2.54K Dec 9, 2022 Direct F1, F2
transaction AVTE Common Stock Sale -$14.7K -583 -22.93% $25.23 1.96K Dec 9, 2022 Direct F1, F3
transaction AVTE Common Stock Options Exercise $21.4K +10K +510.2% $2.14* 12K Dec 12, 2022 Direct F1
transaction AVTE Common Stock Sale -$300K -10K -83.61% $30.04 1.96K Dec 12, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -3.97K -9.75% $0.00 36.8K Dec 9, 2022 Common Stock 3.97K $2.14 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -7.09K -19.3% $0.00 29.7K Dec 12, 2022 Common Stock 7.09K $2.14 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -2.91K -3.51% $0.00 79.9K Dec 12, 2022 Common Stock 2.91K $2.14 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $25.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.39, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F6 A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer